



#### **CME Information**

#### Jointly provided by Postgraduate Institute for Medicine, DKBmed, and the Institute for Johns Hopkins Nursing.

#### Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

Name of Faculty or Presenter	Reported Financial Relationship
Paul G. Auwaerter, MD, MBA, FIDSA	JNJ: Ownership equity Scientific Consulting: Verily, EMD Serono DMSB: Humanigen

Dr. Auwaerter has indicated that he will be referencing the unlabeled or unapproved use of agents currently being investigated in on-going studies and trials, including monoclonal antibodies, baricitinib, and several vaccine platforms.

All activity, content, and materials have been developed solely by the activity directors, planning committee members, and faculty presenters, and are free of influence from a commercial entity.



# To attest for CME/CE/AAPA credit, please visit COVID19.dkbmed.com



# **Learning Objectives**

Discuss the current knowledge of the omicron variant



This activity is supported by an educational grant from Gilead Sciences, Inc. and in-kind support by DKBmed LLC

All activity content and materials have been developed solely by the activity directors, planning committee members, and faculty presenters.

Please see **COVID19.DKBmed.com** for additional resources and educational activities



### Paul Auwaerter, MD, MBA, FIDSA

Clinical Director, Division of Infectious Diseases Sherrilyn and Ken Fisher Professor of Medicine Fisher Center for Environmental Infectious Diseases Johns Hopkins University School of Medicine



# **Omicron**

The latest VOC: B.1.1.529 novel variant SARS-CoV-2



# University Students on Bus Trip to Western Cape, South Africa






### **Omicron: Easier Detection?**

- Some SARS-CoV-2 PCR uses three target genes
  - o e.g., ThermoFisher TacMan platform
- Omicron: one is not detected
  - called S gene dropout or S gene target failure
- Early identification as a marker for this variant pending sequencing confirmation
- Manufacturers assessing ability of their molecular platforms to detect Omicron


Rapid assessment in S. Africa
University outbreak (samples from Nov 12-16, 2021) led to detection of Omicron





# **Gauteng Province**


- 90% of SARS-CoV-2 isolates sequenced = Omicron
- Younger population
  - o Mild illness?
  - Too early to understand transmissibility
  - No increase in hospitalizations (yet)
- Wastewater analysis in Pretoria RNA virus levels similar to Delta surge in May '21






# Omicron changes and theoretical problems

- 50 mutations in total
  - o 30 in spike protein
- Incorporates mutations seen in
  - Alpha
  - Beta
  - Gamma
  - Delta
- Mutations in RBD + nucleoprotein
   resistance to neutralizing abs?
- Nucleocapsid mutations = increased transmissibility?





# **More Transmissible?**





# South Africa SARS-CoV-2 Cases





#### **Omicron Unknowns**

- Degree of spread
  - Isolates detected in Botswana, Hong Kong, Canada, UK, Belgium
- Transmissibility
- Severity
- Impact on vaccine-induced neutralizing antibodies





Do you think the rapid antigen tests can detect omicron variant?





Will remdesivir and monoclonal antibodies still be active against this variant?





What are your recommendations about holiday and travel plans, particularly in light of this variant?



#### To receive CME/CE/AAPA credit:

Complete the evaluation on at COVID19.DKBmed.com Upon registering and successfully completing the activity evaluation, you will have immediate access to your certificate.

#### To access more resources related to COVID-19:

Access our resource hub at COVID19.DKBmed.com

## To ask your own question, email:

QA@dkbmed.com